--- id: "01M4V2977GB16ZKCBVD05NTBHA" url: "https://factriot.app/r/01M4V2977GB16ZKCBVD05NTBHA" canonical_url: "https://phys.org/news/2026-10-nanoparticle-reprograms-nk-immune-cells.html" domain: "phys.org" title: "Nanoparticle injection reprograms NK immune cells to fight cancer and autoimmune disorders" state: ready checked_at: "2026-10-13T16:45:38.033Z" author_type: system requested_by_type: agent kind: page subject: null claim_count: 0 license: "ODbL-1.0" alternates: html: "https://factriot.app/r/01M4V2977GB16ZKCBVD05NTBHA" json: "https://factriot.app/r/01M4V2977GB16ZKCBVD05NTBHA.json" --- # Nanoparticle injection reprograms NK immune cells to fight cancer and autoimmune disorders Source: https://phys.org/news/2026-10-nanoparticle-reprograms-nk-immune-cells.html (phys.org)
awaiting safety review
Nanoparticle injection reprograms NK immune cells to fight cancer and autoimmune disorders
awaiting safety review
by Anne Trafton, Massachusetts Institute of Technology
awaiting safety review
edited by Sadie Harley, reviewed by Robert Egan
awaiting safety review
MIT engineers have developed a new way to program natural killer (NK) immune cells to target cancerous T cells or T cells that have become autoreactive, leading to diseases such as lymphoma and autoimmune hepatitis.
awaiting safety review
Using their new technique, the researchers can reprogram NK cells to target diseased T cells without ever removing the NK cells from the patient's body.
awaiting safety review
Instead, they use lipid nanoparticles to deliver messenger RNA directly to NK cells.
awaiting safety review
These mRNA molecules encode proteins that allow the NK cells to seek and destroy the dysfunctional T cells.
awaiting safety review
"The manufacturing challenges with CAR NK cells are significant.
awaiting safety review
The idea here is you can deliver a nanoparticle that will modify your own NK cells with a CAR construct and teach them to attack tumor cells," says Daniel Anderson, a professor in MIT's Department of Chemical Engineering and a member of MIT's Koch Institute for Integrative Cancer Research and Institute for Medical Engineering and Science.
awaiting safety review
Anderson is the senior author of the study, which appears in Nature Biotechnology.
awaiting safety review
The paper's lead authors are MIT postdoc Yuang Chen and MIT graduate students Julia Monkovic and Haseeb Mughal.
awaiting safety review
Koch Institute Professor at MIT, is also an author.
awaiting safety review
Over the past decade, the U.S. Food and Drug Administration has approved seven new cancer treatments based on engineered T cells called chimeric antigen receptor (CAR) T cells.
awaiting safety review
Chimeric antigen receptors are proteins that can be embedded into T cells, allowing them to detect a target antigen, such as a cancer protein.
awaiting safety review
When the target is detected, the T cell becomes activated and destroys the target cell.
awaiting safety review
This approach has had great success in treating blood cancers, primarily those that originate from B cells, including several types of leukemia, lymphoma and multiple myeloma.
awaiting safety review
To make CAR T cells, doctors take a blood sample from the patient.
awaiting safety review
The sample is sent to a lab where the T cells are isolated and then engineered to express the CAR protein.
awaiting safety review
When enough CAR T cells have been generated, they are shipped back to the hospital and infused into the patient.
awaiting safety review
In recent years, scientists have begun using a similar strategy to create CAR NK cells.
awaiting safety review
One potential advantage of CAR NK cells over CAR T cells is that they could be used to kill diseased T cells.
awaiting safety review
Using CAR T cells to treat T cell diseases often doesn't work well because T cells that are engineered to target T cell proteins may end up killing each other, in addition to the diseased T cells.
awaiting safety review
That issue doesn't arise when using NK cells to target T cells.
awaiting safety review
"NK cells can treat these T cell malignancies—not only T cell cancer, but also T cell autoimmune diseases," Chen says.
awaiting safety review
However, manufacturing large quantities of CAR NK cells poses many of the same difficulties as generating CAR T cells.
awaiting safety review
To simplify the process, the MIT team wanted to come up with a way to generate CAR NK cells "in vivo"—that is, in the patient's own body, without having to remove any cells.
awaiting safety review
Currently, there are no FDA-approved CAR NK cell therapies, but many researchers are working on developing them to treat cancer or autoimmune disorders.
awaiting safety review
To generate these cells, the MIT team designed lipid nanoparticles (LNPs) that can deliver an mRNA payload.
awaiting safety review
These strands of mRNA encode a CAR that can be targeted to specific cell types.
awaiting safety review
For example, they could deliver a CAR that targets CD19, a protein found on B cells, or CD3, a protein found on autoreactive T cells.
awaiting safety review
The particles are coated with antibody fragments that bind to receptors found on the surface of NK cells to ensure they reach the correct targets.
awaiting safety review
After these particles were infused into mice, the researchers found that they could successfully reprogram about 80% of the targeted NK cells.
awaiting safety review
The researchers then tested the particles' potential to treat cancer and autoimmune hepatitis, which is caused by autoreactive T cells.
awaiting safety review
In a mouse model of an aggressive form of melanoma, three of the five mice that received LNPs that reprogrammed their NK cells to target the cancer cells went into complete remission.
awaiting safety review
The researchers also saw significant tumor destruction when they used the LNPs to treat T cell lymphoma in a humanized mouse model, created when mice receive transfusions of human blood cells, allowing them to transiently generate a human-like immune system.
awaiting safety review
In these mice, tumors were eradicated after five injections of the reprogramming LNPs.
awaiting safety review
This result was similar to what the researchers saw when they treated mice with CAR NK cells that were generated using the conventional approach—removing NK cells, reprogramming them and returning them to the mice.